Guidance, NICE advice and quality standards in development | Guidance

Showing 121 to 130 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]	Technology appraisal guidance	21 August 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Ex-situ machine perfusion devices for liver transplants	Health technology evaluation	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Familial Breast Cancer: initial assessment and genetic testing (update)	NICE guideline	31 January 2027
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment - update 1 and 2	NICE guideline	TBC